The focus of the Human Imaging Core (Director: Dr. Bradley Erickson) is to provide critical human imaging capabilities to MTPC investigators and extended national and international faculty by making a variety of services available. These include imaging protocol development; image transfer, management and storage; volumetric and other quantitative analysis (cyst distribution, cyst parenchyma-surface area, Dual energy CT) and advanced MR imaging analysis (renal blood flow measurements, intracranial aneurysm detection, and MR elastography) of affected organs in ADPKD. During the past grant cycle to date, the Human Imaging Core has provided image analysis for six NIH, two PKD Foundation, five industry, and three Mayo funded clinical studies or trials. These include volumetric analysis of 2,669 CT and 2,434 MR scans of kidneys or livers, in addition to MR measurements of RBF and other image analyses in a smaller number of patients. The volumetric analysis alone has taken approximately 5,613 hours. The Human Imaging Core has also assisted in the design and management of MR images from Mayo patients with ADPKD participating in multicenter clinical trials (CRISP and HALT) and the protocol development for DIPAK 1 (a clinical trial of Lanreotide supported by the Dutch Kidney Foundation and IPSEN Pharmaceutica). In addition, six new core services that were developed during the prior period: automated kidney segmentation from stereology, image-based classification of patients, magnetic resonance elastography, dual energy CT to characterize renal stones, renal blood flow, cyst- parenchyma surface area, are now available to researchers. Furthermore, the Human Imaging Core actively develops new technologies to enhance the breadth of offerings or the value of the current services. Technologies under development include: novel imaging methods for characterizing PKD (magnetization transfer imaging, diffusion, and blood-oxygen level determination) and differentiating cysts and parenchymal tissues. In addition to providing the services, the core offers training in these techniques. The core has educated and trained a large number of individuals from across the world on the proper use of tools to measure TKV and has also shared some of our algorithms developed in the past grant cycle. For these reasons, we believe that the Human Imaging Core is a critical resource for the study of PKD, and is a unique strength of the current application, as no other PKD Center has such a core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK090728-07
Application #
9144762
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Masyuk, Anatoliy I; Masyuk, Tatyana V; Lorenzo Pisarello, Maria J et al. (2018) Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology 67:1088-1108
Lakhia, Ronak; Yheskel, Matanel; Flaten, Andrea et al. (2018) PPAR? agonist fenofibrate enhances fatty acid ?-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol Renal Physiol 314:F122-F131
Boczek, Nicole J; Hopp, Katharina; Benoit, Lacey et al. (2018) Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet 26:1797-1809
Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492
Wong, Annette T Y; Mannix, Carly; Grantham, Jared J et al. (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier et al. (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33:477-489
Higashihara, Eiji; Horie, Shigeo; Kinoshita, Moritoshi et al. (2018) A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. Clin Exp Nephrol 22:395-404
Kline, Timothy L; Edwards, Marie E; Garg, Ishan et al. (2018) Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY) 43:629-638
Chebib, Fouad T; Torres, Vicente E (2018) Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 13:1765-1776

Showing the most recent 10 out of 192 publications